This story explores how potential demand for rarer cannabinoids is prompting firms to explore other methods of manufacturing, such as biosynthesis and chemical synthesis, to give higher yields at lower cost.
These rarer cannabinoids are being trialled for potential therapeutic effects of a range of physical and mental conditions.
The story examines the development efforts of three North American companies in particular to research effects and to achieve economical production.
...Are you already a subscriber? login here
Need help?
Contact a sales representative right now and don’t wait
Erik Galavis
+34 654 320 547
Email Erik
Pablo Sharrock
+34 722 642 678
Email Pablo
